Jubilant Ingrevia shares rise after strong Q2 earnings
after close1 source ↓machine-written, see hownot a recommendation
Jubilant Ingrevia shares rose more than 8% on Tuesday, 27 Oct 2026, after the speciality chemicals company reported a strong September-quarter performance. Consolidated net profit increased 61.4% year on year to ₹111.4 crore, while revenue grew 24.4% to ₹1,394.2 crore from ₹1,121 crore in the year-ago quarter. 📈
Key Points:
• EBITDA rose 56.4% year on year to ₹212.4 crore from ₹135.8 crore.
• EBITDA margin expanded to 15.2% from 12.1%, a 310-basis-point improvement.
• Profit before tax increased to ₹148.5 crore from ₹94.6 crore in the corresponding quarter last year.
• The Nutrition & Health Solutions business supported the earnings improvement, according to the report.
The results matter because earnings growth exceeded revenue growth, indicating that operating profitability improved alongside higher sales. The wider margin expansion gives the speciality chemicals segment a stronger earnings profile, particularly as investors assess whether improved product mix and segment performance can support profitability across cycles. 🧪
The immediate market reaction reflects the combination of double-digit revenue growth, a 61.4% rise in net profit and stronger operating leverage. The reported EBITDA margin improvement is also important for tracking the company’s ability to convert sales into operating earnings. The figures provide an earnings-based catalyst for the stock, while the next phase of trading will depend on how the market evaluates the durability of these gains.
Investors will watch the company’s commentary on Nutrition & Health Solutions, demand conditions across its speciality chemicals portfolio and the sustainability of the 15.2% EBITDA margin. The next quarterly update will provide the clearest comparison for whether the September-quarter improvement was maintained. Further attention will also remain on revenue growth, operating costs and the movement of profit before tax.
The latest performance follows a year-on-year comparison that showed significant improvement across revenue, EBITDA, margins and profit. With the stock already gaining more than 8% during Tuesday’s session, subsequent price action will reflect whether the reported earnings strength continues to influence sentiment in the speciality chemicals sector.
Source: CNBC TV18, 27 Oct 2026
Not investment advice. For informational purposes only.